WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205864
Description: Balixafortide, also known as POL6326, is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor POL6326 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.
MedKoo Cat#: 205864
Chemical Formula: C80H112N22O21S2
Exact Mass: 1780.7814
Molecular Weight: 1782.029
Elemental Analysis: C, 53.92; H, 6.34; N, 17.29; O, 18.85; S, 3.60
Synonym: POL6326; POL 6326; POL6326; Balixafortide; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide
IUPAC/Chemical Name: Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide
InChi Key: UUTLJGUXRVWOSI-YYXAXUJHSA-N
InChi Code: InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1
SMILES Code: C[C@H]1C(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N1)=O)CO)=O)NC([C@H](C)N)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N4CCC[C@H]4C(N5CCC[C@H]5C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@@H](CC7=CNC=N7)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC8=CC=C(C=C8)O)=O)CCCNC(N)=N)=O)=O
POL6326 has successfully completed Phase I clinical trials and is currently being investigated as a stand-alone therapy in a Phase II clinical trial for its efficacy in autologous transplantation of hematopoietic stem cells in multiple myeloma patients. Interim results of the Phase II trial reveal that POL6326 is safe and well tolerated by all enrolled patients. The interim results also show efficacy, in particular a rapid and predictable onset and a dose-dependent mobilization of stem cells. The mobilization, collection of stem cells from the circulating blood (apheresis), analysis and processing of stem cells is completed in one day which represents an important competitive advantage in the hospital compared to standard therapy. (source: http://www.polyphor.com/pol6326.html).